Author  
Place of duty  
Title   소세포 폐암에 대한 VP-16 , Cisplatin 복합화학요법치료 효과 ( VP-16 and Cisplatin Combination Chemotherapy in Small Cell Lung Cancer )
Publicationinfo   1995 Jan; 027(01): 77-84.
Key_word   Mitomycin C, Vinblastine, Cisplatin, MVF, Chemotherapy, Non-small cell lung cancer
Full-Text  
Abstract   Objectives: Despite recent advances in chemotherapy, the treatment outcome of advanced non-small cell lung cancer(NSCLC) remains poor and NSCLC is still the predominant source of cancer-related mortality in worldwide. Thus, we evaluated the efficacy and safety of a combination chemotherapy with mitomycin C, vinblastine, and cisplatin(MVP) in advanced NSCLC patients in Korea. Methods; Cisplatin was infused intravenously at a dose 20 mg/m from 1st to 5th day and mitomycin C 10 mg/m and vinblastine 6 mg/m were given intravenously on day 1. This treatment schedule was repeated every 3 weeks. Results: Among 94 evaluable patients, overall response rate was 44% including 4% of complete response. Squamous cell carcinoma responded better than adenocarcinoma. The median time to progression was 24 weeks and the median survival time was 42 weeks. Statistically significant survival advantage was observed in responder group(60 weeks vs. 36 weeks). The toxicities of this regimen were mild and well tolerated. Conclusion: In advanced NSCLC, MVP combination chemotherapy is relatively effective and safe.
저 자   김재석(Jae Seok Kim),권혁찬(Hyuk Chan Kwon),배성진(Sung Jin Bae),노명환(Myung Hwan Noh),정원태(Won Tae Chung),김효진(Hyo Jin Kim),강창운(Chang Woon Kang),김종성(Jong Seong Kim)